Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy

Seminars in Immunology

Volumn 22, Issue 3, 2010, Pages 183-189

  Paterson, Yvonne ^a   Guirnalda, Patrick D ^a   Wood, Laurence M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Listeria monocytogenes; Salmonella enterica; Tumor immunotherapy; Tumor vasculature; Tumor associated antigens

Indexed keywords

BACTERIAL TOXIN; BACTERIAL VECTOR; BCG VACCINE; CHOLERA TOXIN B SUBUNIT; COMPLEMENTARY DNA; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MELANOMA ANTIGEN; MESSENGER RNA; NY ESO 1 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN E7; TUMOR ANTIGEN; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR; ANGIOGENESIS INHIBITOR; RECOMBINANT PROTEIN;

ANTIGEN PRESENTING CELL; ANTIGENICITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; GENETIC TRANSFECTION; HUMAN; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MICROBIAL ACTIVITY; MICROBIOLOGY; NONHUMAN; REVIEW; SALMONELLA ENTERICA; TUMOR VASCULARIZATION; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, NEOPLASM; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; MICE; NEOPLASMS; RECOMBINANT PROTEINS; SALMONELLA ENTERICA;

EID: 77953547319     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2010.02.002     Document Type: Review

References (77)

1. Van den Eynde B., Hainaut P., Hérin M., et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989, 44:634-640.
2. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 2003, 21:807-839.
3. McCarthy E.F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006, 26:154-158.
4. Shelly M.D., Kynaston H., Court J., et al. A systemic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001, 88:209-216.
5. Rapp N.S., Gilroy J., Lerner A.M. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995, 74:415-418.
6. Buchmeier N.A., Heffron F. Inhibition of macrophage phagosome-lysosome fusion by Salmonella typhimurium. Infect Immun 1991, 59:2232-2238.
7. Alpuche-Aranda C.M., Racoosin E.L., Swanson J.A., et al. Salmonella stimulate macrophage macropinocytosis and persist within spacious phagosomes. J Exp Med 1994, 179:601-608.
8. Birmingham C.L., Canadien V., Kaniuk N.A., et al. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 2008, 451:350-354.
9. Portnoy D.A., Chakraborty T., Goebel W., et al. Molecular determinants of Listeria monocytogenes pathogenesis. Infect Immun 1992, 60:1263-1267.
10. Southwick F.S., Purich D.L. Listeria and Shigella actin-based motility in host cells. Trans Am Clin Climatol Assoc 1998, 109:160-173.
11. Cossart P., Pizarro-Cerdá J., Lecuit M. Invasion of mammalian cells by Listeria monocytogenes: functional mimicry to subvert cellular functions. Trends Cell Biol 2003, 13:23-31.
12. Biron C.A., Gazzinelli R.T. Effects of IL-12 on immune responses to microbial infections: a key mediator in regulating disease outcome. Curr Opin Immunol 1995, 7:485-496.
13. Pamer E.G., Sijts A.J., Villanueva M.S., et al. MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses. Immunol Rev 1997, 158:129-136.
14. Mackaness G.B. The immunological basis of acquired cellular resistance. J Exp Med 1964, 120:105-120.
15. Weiskirch L.M., Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol Rev 1997, 158:159-169.
16. Schafer R., Portnoy D.A., Brassell S.A., et al. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol 1992, 149:53-59.
17. Paterson Y., Johnson R.S. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004, 3:S119-S134.
18. Seavey M.M., Verch T., Paterson Y. Anticancer vaccine strategies. Handbook of Listeria monocytogenes 2008, 481-511. CRC Press. D. Liu (Ed.).
19. Wood L.M., Guirnalda P.G., Seavey M.M., et al. Cancer immunotherapy using Listeria monocytogenes and Listerial virulence factors. Immunol Res 2008, 42:233-245.
20. Wallecha A., Carroll K.D., Maciag P.C., et al. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anti-cancer immunotherapeutics. Adv Appl Microbiol 2009, 66:1-27.
21. Gunn G.R., Zubair A., Peters C., et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001, 167:6471-6479.
22. Sewell D.A., Douven D., Pan Z.K., et al. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg 2004, 130:92-97.
23. Rogers S., Wells R., Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986, 234:364-368.
24. Sewell D.A., Shahabi V., Gunn G.R., et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 2004, 64:8821-8825.
25. Mengaud J., Vicente M.F., Cossart P. Transcriptional mapping and nucleotide sequence of the Listeria monocytogenes hlyA region reveal structural features that may be involved in regulation. Infect Immun 1989, 57:3695-3701.
26. Sewell D.A., Pan Z.-K., Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008, 26:5322-5327.
27. Singh R., Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 2007, 67:1887-1892.
28. + breast tumors. Clin Cancer Res 2009, 15:924-932.
29. Singh R., Dominiecki M.E., Jaffee E.M., et al. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 2005, 175:3663-3673.
30. Ercolini A.M., Machiels J.P., Chen Y.C., et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 2003, 170:4273-4280.
31. Singh R., Paterson Y. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res 2006, 66:7748-7757.
32. Schödel F., Curtiss R. Salmonellae as oral vaccine carriers. Dev Biol Stand 1995, 84:245-253.
33. Medina E., Guzmán C.A., Staendner L.H., et al. Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. Eur J Immunol 1999, 29:693-699.
34. Medina E., Paglia P., Rohde M., et al. Modulation of host immune response stimulated by Salmonella vaccine carrier strains by using different promoters to drive the expression of the recombinant antigen. Eur J Immunol 2000, 30:768-777.
35. Revaz V., Benyacoub J., Kast W.M., et al. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 2001, 279:354-360.
36. Stark F.C., Sad S., Krishnan L. Intracellular bacterial vectors that induce CD8(+) T cells with similar cytolytic abilities but disparate memory phenotypes provide contrasting tumor protection. Cancer Res 2009, 69:4327-4334.
37. Nishikawa H., Sato E., Briones G., et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006, 116:1946-1954.
38. + T cells by a bacterial vector. Blood 2008, 111:1404-1412.
39. Fensterle J., Bergmann B., Yone C.L., et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther 2008, 15:85-93.
40. Pilgrim S., Stritzker J., Schoen C., et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther 2003, 10:2036-2045.
41. Donnelly J.J., Ulmer J.B., Shiver J.W., et al. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
42. Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
43. + T lymphocyte responses. Eur J Immunol 2004, 34:1011-1020.
44. + T cell responses. Cancer Immunol Immunother 2007, 56:797-806.
45. Reisfeld R.A., Niethammer A.G., Luo Y., et al. DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 2004, 199:181-190.
46. Chou C.K., Hung J.Y., Liu J.C., et al. An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alpha-fetoprotein. Cancer Gene Ther 2006, 13:746-752.
47. Xiang R., Lode H.N., Chao T.H., et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000, 97:5492-5497.
48. Weth R., Christ O., Stevanovic S., et al. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther 2001, 8:599-611.
49. Xiang R., Silletti S., Lode H.N., et al. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin Cancer Res 2001, 3(Suppl.):856s-864s.
50. Xiang R., Primus F.J., Ruehlmann J.M., et al. Dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice. J Immunol 2001, 167:4560-4565.
51. Luo Y., Zhou H., Mizutani M., et al. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci USA 2003, 100:8850-8855.
52. Niethammer A.G., Wodrich H., Loeffler M., et al. Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J 2005, 19:158-159.
53. Dietrich G., Bubert A., Gentschev I., et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol 1998, 16:181-185.
54. Spreng S., Dietrich G., Niewiesk S., et al. Novel bacterial systems for the delivery of recombinant protein or DNA. FEMS Immunol Med Microbiol 2000, 27:299-304.
55. Souders N.C., Verch T., Paterson Y. In vivo bactofection: Listeria can function as a DNA-cancer vaccine. DNA Cell Biol 2006, 25:142-151.
56. Loeffler D.I., Schoen C.U., Goebel W., et al. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect Immun 2006, 74:3946-3957.
57. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182-1186.
58. Esteva F.J. Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 2004, 9(Suppl. 3):4-9.
59. Zwaans B.M., Bielenberg D.R. Potential therapeutic strategies for lymphatic metastasis. Microvasc Res 2007, 74:145-158.
60. Betsholtz C., Lindblom P., Gerhardt H. The role of pericytes in vascular morphogenesis. EXS 2005, 94:115-125.
61. O'Keeffe M.B., Devlin A.H., Burns A.J., et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol Res 2008, 17:93-101.
62. Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167-168.
63. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. Endothelium 2006, 13:63-69.
64. Niethammer A.G., Xiang R., Becker J.C., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002, 8:1369-1375.
65. Luo Y., Markowitz D., Xiang R., et al. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine 2007, 25:1409-1415.
66. Xiang R., Luo Y., Niethammer A.G., et al. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. Immunol Rev 2008, 222:117-128.
67. Lee S.H., Mizutani N., Mizutani M., et al. Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 2006, 55:1565-1574.
68. Kaplan C.D., Krüger J.A., Zhou H., et al. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 2006, 24:6994-7002.
69. + breast tumors in a mouse model. J Immunol 2009, 182:5537-5546.
70. Schlingemann R.O., Rietveld F.J., de Waal R.M., et al. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990, 136:1393-1405.
71. Campoli M.R., Chang C.C., Kageshita T., et al. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004, 24:267-296.
72. Maciag P.C., Seavey M.M., Pan Z.K., et al. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008, 68:8066-8075.
73. Old L.J. Cancer vaccines: an overview. Cancer Immun 2008, 8(Suppl. 1):1.
74. Maciag P.C., Radulovic S., Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009, 27:3975-3983.
75. Galen J.E., Pasetti M.F., Sztein M.B., et al. Attenuated Salmonella and Shigella as live vectors carrying either prokaryotic or eukaryotic expression systems. New generation vaccines 2004, 354-366. Marcel Dekker. 3rd ed. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, M.F. Good (Eds.).
76. Peters C., Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine 2003, 21:1187-1194.
77. Leong M.L., Hampl J., Liu W., et al. Impact of preexisting vector-specific immunity on vaccine potency: characterization of Listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice. Infect Immun 2009, 77:3958-3968.